 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
Parc Biocitech, 102 route de Noisy
93230 Romainville
France
|
|
Portrait
Founded in 2003, Endotis Pharma is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology. Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds, either in-licensed (from Organon: EP42675, an anticoagulant that has completed two phase I, EP217609, the neutralizable form of EP4675 and EP224283, an antithrombotic which is in preclinicals) or generated by the company's own drug discovery platform (EP37 program, focused on the oral prevention and treatment of thrombosis, and EP8000 program in oncology). The SGDs developed by Endotis are based on fully synthetic oligosaccharides mimicking glycosaminoglycans, which is the core field of expertise of Endotis' scientists. Proof of concept has already been established with synthetic oligosaccharides in cardiovascular/thrombosis, with oncology being the next promising therapeutic area. Endotis currently has 26 employees (including 14 PhDs/MDs) based in Paris and Lille (France). Sofinnova Partners is a lead investor in Endotis Pharma.
Industrial Sectors
Additional information
Endotis Pharma SA
Romainville, France
News
|
|
|
|
|
|
Top
